Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.45 |
| ▸ | FDPS | P14324 | 8/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL10601124 | 1.00 | CES2 (0.47) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL4361811 | 0.98 | CES2 (0.48) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL5027714 | 0.96 | CES2 (0.44) | CES2GGPS1FDPSEPHX1 | |
| SCHEMBL8898953 | 0.93 | CES2 (0.41) | CES2GGPS1FDPSCES1 | |
| SCHEMBL5032181 | 0.89 | CES2 (0.42) | CES2GGPS1FDPSEPHX1 | |
| SCHEMBL6918609 | 0.88 | CES2 (0.45) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL5171452 | 0.88 | CES2 (0.45) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL2709008 | 0.88 | CES2 (0.45) | CES2GGPS1FDPSEPHX1CES1 | |
| SCHEMBL5030363 | 0.86 | CES2 (0.44) | CES2GGPS1FDPSEPHX1 | |
| SCHEMBL29406337 | 0.86 | CYP4F2 (0.42) | CES2GGPS1FDPSCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3760619-A1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111741948-A | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2020-10-02 | — | — | CN | disclosed |
| US-20190300490-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2019-10-03 | — | — | US | disclosed |
| US-8367623-B2 | Glycolipid and medicine for autoimmune disease containing the same as active ingredient | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-1437358-B1 | NOVEL GLYCOLIPID AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20060148723-A1 | Novel glycolipid and medicine for autoimmune disease containing the same as active ingredient | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1437358-A1 | NOVEL GLYCOLIPID AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-5194634-A | Coenzyme A inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-03-16 | — | — | US | disclosed |
| US-5157134-A | HMG-COA reductase inhibitors; antilipemic agents; promotes high-density lipoproteins; antitumor agents | E. R. SQUIBB & SONS, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300490-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | CES2 4253/4885GGPS1 517/4885FDPS 191/4885 |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | CES2 4341/4885GGPS1 590/4885FDPS 232/4885 |
| US-20060148723-A1 | Novel glycolipid and medicine for autoimmune disease containing the same as active ingredient | SGMS1, ZDHHC20, UGCG | CES2 2199/4885GGPS1 510/4885FDPS 1998/4885 |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | CES2 4341/4885GGPS1 590/4885FDPS 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.